冠心病患者半乳糖凝集素-3與冠脈病變程度及預后的相關性研究
發(fā)布時間：2018-08-18 16:28
【摘要】：目的：通過檢測冠心病患者血清半乳糖凝集素-3(Galectin-3)水平,分析其在不同類型冠心病患者中的水平及分別與Gensini積分、B型腦鈉肽(BNP)的相關性,并觀察其與冠心病患者主要心血管事件(MACE)發(fā)生的關系,初步探討冠心病患者血清Galectin-3水平與冠狀動脈病變程度及預后關系。方法：收集我院自2013年7月至2014年3月因胸痛于我科住院診治,根據(jù)臨床表現(xiàn)、心電圖、心肌酶或冠狀動脈造影(CAG)結(jié)果確診為冠心病(CAD)的患者。從上述CAD患者中隨機選取40例穩(wěn)定性心絞痛(SA)患者作為A組,40例不穩(wěn)定性心絞痛(UA)患者作為B組,40例急性心肌梗死(AMI)患者作為C組,共120例。收集我院體檢中心行健康查體的40位健康者作為正常對照組(D組)。應用酶聯(lián)免疫吸附法(ELISA)檢測所有研究對象的血清Galectin-3水平,化學發(fā)光法檢測BNP水平。冠脈狹窄程度采用用Gensini積分系統(tǒng)進行估測。對120例CAD患者進行1年的隨訪,記錄隨訪期間發(fā)生的MACE。結(jié)果：1.CAD患者血清Galectin-3水平高于正常對照組,且C組患者血清Galectin-3水平高于B組,B組患者血清Galectin-3水平高于A組,除B組與C組患者血清Galectin-3水平無統(tǒng)計學差異(p=0.197)外,其它各組間均有統(tǒng)計學顯著性差異(p0.01)。2.Spearman相關分析表明,Galectin-3與Gensini評分、BNP呈正相關。3.隨訪1年,15例患者出現(xiàn)MACE。與無不良心血管事件組相比,有心血管不良事件組患者血清Galectin-3水平顯著升高,統(tǒng)計學有顯著性差異(p0.05)4.多因素Logistic回歸分析表明,冠心病患者血清Galectin-3 (OR=1.157, CI:1.047-1.279,p0.01)、BNP(OR=1.010,CI: 1.000-1.034,p0.028)水平與其不良預后呈正相關。結(jié)論：1.冠心病患者血清Galectin-3水平可能與AS的形成斑塊不穩(wěn)定性相關。2.冠心病患者血清Galectin-3水平與冠狀動脈病變嚴重程度呈正相關。3.Galectin-3可能促進冠狀動脈粥樣硬化的發(fā)生、發(fā)展及心室重塑。4.血清Galectin-3水平高的CAD患者可能預后不良。
[Abstract]:Objective: to detect the level of serum galactose agglutinin 3 (Galectin-3) in patients with coronary heart disease (CHD) and its correlation with Gensini integral type B brain natriuretic peptide (BNP). The relationship between serum Galectin-3 level and the severity and prognosis of coronary artery disease (CHD) was investigated by observing the relationship between serum Galectin-3 level and the occurrence of main cardiovascular events (MACE) in patients with coronary heart disease (CHD). Methods: from July 2013 to March 2014, patients with coronary heart disease (CAD) were diagnosed as coronary heart disease (CHD) according to clinical manifestation, electrocardiogram (ECG), myocardial enzyme or coronary angiography (CAG). Forty patients with stable angina pectoris (SA) were randomly selected as group A and 40 patients with unstable angina pectoris (UA) as group B and 40 patients with acute myocardial infarction (AMI) as group C. A total of 40 healthy subjects were collected from our physical examination center as the normal control group (group D). Enzyme linked immunosorbent assay (ELISA) was used to detect the level of serum Galectin-3 and chemiluminescence to detect the level of BNP. The degree of coronary stenosis was estimated by Gensini integral system. 120 patients with CAD were followed up for 1 year. Results 1. The level of serum Galectin-3 in patients with CAD was higher than that in normal controls, and the level of serum Galectin-3 in group C was higher than that in group B (P < 0. 197). The level of serum Galectin-3 in group B was higher than that in group A (P < 0. 197). 2. Spearman correlation analysis showed that Galectin-3 was positively correlated with Gensini score. 15 patients were followed up for 1 year. Compared with the non-adverse cardiovascular events group, the serum Galectin-3 level of the patients with cardiovascular adverse events was significantly higher than that of the non-adverse cardiovascular events group (p0.05) 4. Multivariate Logistic regression analysis showed that the level of serum Galectin-3 (OR 1.157, CI: 1.047-1.279 / p0.01) was positively correlated with the poor prognosis in patients with coronary heart disease (OR 1.010 CI: 1.000-1.034 P 0.028). Conclusion 1. The serum Galectin-3 level in patients with coronary heart disease may be related to plaque instability. 2. 2. The level of serum Galectin-3 was positively correlated with the severity of coronary artery disease. 3. Galectin-3 may promote the occurrence, development and ventricular remodeling of coronary atherosclerosis. CAD patients with high serum Galectin-3 level may have poor prognosis.
【學位授予單位】：濱州醫(yī)學院
【學位級別】：碩士
【學位授予年份】：2015
【分類號】：R541.4
本文編號：2190030
[Abstract]:Objective: to detect the level of serum galactose agglutinin 3 (Galectin-3) in patients with coronary heart disease (CHD) and its correlation with Gensini integral type B brain natriuretic peptide (BNP). The relationship between serum Galectin-3 level and the severity and prognosis of coronary artery disease (CHD) was investigated by observing the relationship between serum Galectin-3 level and the occurrence of main cardiovascular events (MACE) in patients with coronary heart disease (CHD). Methods: from July 2013 to March 2014, patients with coronary heart disease (CAD) were diagnosed as coronary heart disease (CHD) according to clinical manifestation, electrocardiogram (ECG), myocardial enzyme or coronary angiography (CAG). Forty patients with stable angina pectoris (SA) were randomly selected as group A and 40 patients with unstable angina pectoris (UA) as group B and 40 patients with acute myocardial infarction (AMI) as group C. A total of 40 healthy subjects were collected from our physical examination center as the normal control group (group D). Enzyme linked immunosorbent assay (ELISA) was used to detect the level of serum Galectin-3 and chemiluminescence to detect the level of BNP. The degree of coronary stenosis was estimated by Gensini integral system. 120 patients with CAD were followed up for 1 year. Results 1. The level of serum Galectin-3 in patients with CAD was higher than that in normal controls, and the level of serum Galectin-3 in group C was higher than that in group B (P < 0. 197). The level of serum Galectin-3 in group B was higher than that in group A (P < 0. 197). 2. Spearman correlation analysis showed that Galectin-3 was positively correlated with Gensini score. 15 patients were followed up for 1 year. Compared with the non-adverse cardiovascular events group, the serum Galectin-3 level of the patients with cardiovascular adverse events was significantly higher than that of the non-adverse cardiovascular events group (p0.05) 4. Multivariate Logistic regression analysis showed that the level of serum Galectin-3 (OR 1.157, CI: 1.047-1.279 / p0.01) was positively correlated with the poor prognosis in patients with coronary heart disease (OR 1.010 CI: 1.000-1.034 P 0.028). Conclusion 1. The serum Galectin-3 level in patients with coronary heart disease may be related to plaque instability. 2. 2. The level of serum Galectin-3 was positively correlated with the severity of coronary artery disease. 3. Galectin-3 may promote the occurrence, development and ventricular remodeling of coronary atherosclerosis. CAD patients with high serum Galectin-3 level may have poor prognosis.
【學位授予單位】：濱州醫(yī)學院
【學位級別】：碩士
【學位授予年份】：2015
【分類號】：R541.4
【參考文獻】
相關期刊論文 前8條
1 張育民;李慶寬;全勇;史桂霞;肖曉霞;李峰;陳科新;梁薇芬;;急性心肌梗死患者血清半乳糖凝集素3水平與冠狀動脈病變的相關性[J];中國動脈硬化雜志;2014年06期
2 白瑞娜;郗瑞席;馮志博;李立志;;巨噬細胞與動脈粥樣硬化——亞型及功能[J];中國循環(huán)雜志;2014年05期
3 劉蕾;張海芳;王慶玲;;半乳凝素-3在不穩(wěn)定性心絞痛中的診斷價值[J];中外醫(yī)學研究;2013年23期
4 韓雪晶;賈克剛;;半乳糖凝集素3作為心力衰竭新的生物標記物的研究進展[J];中華老年心腦血管病雜志;2013年08期
5 朱雪峰;趙翠萍;;心衰新標記物——半乳糖凝集素3[J];國際心血管病雜志;2013年03期
6 婁域峰;施新萍;黃燕娣;倪一鳴;;半乳糖凝集素-3在急性冠狀動脈綜合征和穩(wěn)定性冠心病診斷中的應用[J];中華急診醫(yī)學雜志;2012年02期
7 陳作強;趙仙先;秦永文;;血漿腦鈉肽在急性冠狀動脈綜合征中的臨床應用進展[J];心血管病學進展;2011年04期
8 唐其東;吳平生;候玉清;黃錚;周忠江;郭志剛;修建成;王月剛;;急性冠脈綜合征和冠脈慢性完全閉塞患者MMP2、MMP9升高及臨床意義[J];南方醫(yī)科大學學報;2009年05期
，本文編號：2190030
本文鏈接：http://www.lk138.cn/yixuelunwen/xxg/2190030.html
最近更新
教材專著
